Dr. Toni Choueiri discusses the results of this study, which appears to show a survival signal, but it is difficult to interpret. 

Joaquim Bellmunt explains a bit about why this trial was not successful and what it means for the field. 

Thomas Hope is quizzed on the results of his study presented at ASCO20.

Mike Atkins describes the results of this study which helps shed light on the role of ipilimumab and nivolumab in this disease. 

Betsy Plimack discusses the updated data with a minimum of 23 months' follow up. Dr. Brian Rini and Professor Tom Powles asks what it adds. 

Mike Morris presents the findings in his prospective study. 

Eric Jonasch discusses his ASCO presentation, which shows significant activity of HIF targeting in renal cancer patients with VHL syndrome. 

Jeremy Warner summarises the recent Lancet paper describing the outcome of cancer patients with COVID-19. 

Joaquim Bellmunt talks about management of muscle invasive bladder cancer prior to the Atezolizumab adjuvant data at ASCO20.